Scarica l'app Stockscreener
2.19
1.86%
0.04
Dopo l'orario di chiusura:
2.14
-0.05
-2.28%
Can-Fite Biopharma Ltd ADR Borsa (CANF) Ultime notizie
Can-Fite secures Australian patent for obesity treatment - Investing.com
Can-Fite's partner Vetbiolix secures $325M deal for dog arthritis drug - Investing.com India
Shifts in the Psoriasis Market Suggest Strong Potential for Emerging Oral Therapies - GlobeNewswire Inc.
Ratios in Focus: Analyzing Can-Fite Biopharma Ltd ADR (CANF)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
What is CANF’s price-to-sales ratio telling us about the company’s value? - US Post News
Taking on analysts’ expectations and winning: Can-Fite Biopharma Ltd ADR (CANF) - SETE News
Analytical Lens: Exploring Can-Fite Biopharma Ltd ADR (CANF)’s Financial Story Through Ratios - The Dwinnex
CANF (Can-Fite Biopharma Ltd ADR) has impressive results - US Post News
List of Israeli Stocks Traded on the NYSE Worth Considering - The Times of Israel
Wearable Devices Ltd. sets annual meeting for September 26 - Investing.com
Can-Fite BioPharma shares upgraded by EF Hutton to Buy on pipeline drugs - Investing.com
GitLab stock maintains buy rating on new release By Investing.com - Investing.com
Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat - Yahoo New Zealand News
Canine arthritis treatment shows promise in clinical study - Investing.com India
Can-Fite reveals adiponectin role in cancer treatment By Investing.com - Investing.com
Was Can-Fite Biopharma Ltd ADR (CANF)'s session last reading good? – US Post News - US Post News
Can-Fite's Namodenoson gains FDA Fast Track for liver cancer - Investing.com India
Can-Fite's Namodenoson gains FDA Fast Track for liver cancer By Investing.com - Investing.com
Can-Fite's Namodenoson advances in Phase III liver cancer trial By Investing.com - Investing.com
Can-Fite BioPharma seeks FDA nod for NASH drug trial By Investing.com - Investing.com
ANVS Stock Quote Price and Forecast - CNN
symbol__ Stock Quote Price and Forecast - CNN
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire
Can-Fite Announces ADS Ratio Change - Business Wire
Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates - Nasdaq
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma - Business Wire
Best Penny Stocks Today | Penny Stocks to Buy Now -TipRanksTipRanks.com - TipRanks
The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Trea - Benzinga
Can-Fite BioPharma (CANF) Stock Price, News & Analysis - MarketBeat
The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And Mo - Benzinga
32 Stocks Moving In Thursday's Mid-Day SessionAEterna Zentaris (NASDAQ:AEZS), ADMA Biologics (NASDAQ:A - Benzinga
10 Biopharmaceutical Companies Trying To Cure Cancer - Yahoo Finance
The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax OfferingiShares B - Benzinga
Secondary Offerings Put A Pause On May's MomentumMynd.ai (AMEX:MYND), Can Fite Biofarma (AMEX:CANF) - Benzinga
28 Stocks Moving In Monday's Pre-Market Session - Benzinga
20 Biggest Mid-Day Gainers For TuesdayAlcoa (NYSE:AA), Biogen (NASDAQ:BIIB) - Benzinga
Can-Fite's Rheumatoid Arthritis Drug Faces Off With Methotrexate In Phase III Trial For $40 Billion Market (NYSE:CANF) - Seeking Alpha
Propanc Health Group Corp : This Company Could Be the Next CETX or CANF - Marketscreener.com
Morning Market GainersCan Fite Biofarma (AMEX:CANF) - Benzinga
Can-Fite BioPharma Begins Trading in U.S. through Launch of ADRs - CNBC
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):